# NCT03260491 (NCT03260491)

> U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03260491
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Non-Small Cell Lung Cancer (NSCLC)
- Interventions: HER3-DXd (FL-DP); HER3-DXd (CTM-1 Lyo-DP); HER3-DXd (CTM-3 Lyo-DP)
- Enrollment: 312
- Primary outcome: Dose-limiting toxicities (DLTs) during dose escalation
- Primary outcome: Summary of adverse events during dose escalation
- Primary outcome: Overall response rate (ORR) assessed by Blinded Independent Central Review (BICR) Committee during dose expansion (Dose Expansion Cohorts 1, 2, 3a, 3b, and Cohort 5)
- Primary outcome: Maximum serum concentration (Cmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohort 4)
- Primary outcome: Area under the serum concentration-time curve from time 0 extrapolated to infinity (AUCinf) and up to last quantifiable time (AUC[last]) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohort 4)

## Indexed commentary on NCT03260491 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03260491